Design Therapeutics Inc (DSGN) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $10.68
• Market Cap: $624.89M
• EPS: $-1.19
• 52-Week High: $11.14
• 52-Week Low: $2.60

Market Sentiment

Design Therapeutics Inc currently has a Bullish sentiment score of 0.19.

About Design Therapeutics Inc

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Carlsbad, California, dedicated to developing innovative therapies for degenerative disorders linked to nucleotide repeat expansions, including Friedreich's ataxia and other central nervous system diseases. The company is advancing a pipeline of proprietary small-molecule drug candidates designed to target the genetic causes of these conditions, aiming to restore normal cellular function and enhance patient outco...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Design Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does DSGN pay dividends?

Design Therapeutics Inc (DSGN) does not currently pay a regular dividend.

What is DSGN's market cap?

Design Therapeutics Inc (DSGN) has a market capitalization of $624.89M with a current stock price of $10.68.